These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36153281)

  • 1. Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes.
    Moriarty PM; Steg PG; McGinniss J; Zeiher AM; White HD; Manvelian G; Pordy R; Loy M; Jukema JW; Harrington RA; Gray JV; Gorby LK; Goodman SG; Diaz R; Bittner VA; Bhatt DL; Szarek M; Schwartz GG;
    J Clin Lipidol; 2022; 16(5):747-756. PubMed ID: 36153281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
    Hagström E; Steg PG; Szarek M; Bhatt DL; Bittner VA; Danchin N; Diaz R; Goodman SG; Harrington RA; Jukema JW; Liberopoulos E; Marx N; McGinniss J; Manvelian G; Pordy R; Scemama M; White HD; Zeiher AM; Schwartz GG;
    Circulation; 2022 Aug; 146(9):657-672. PubMed ID: 35770629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
    Bittner VA; Szarek M; Aylward PE; Bhatt DL; Diaz R; Edelberg JM; Fras Z; Goodman SG; Halvorsen S; Hanotin C; Harrington RA; Jukema JW; Loizeau V; Moriarty PM; Moryusef A; Pordy R; Roe MT; Sinnaeve P; Tsimikas S; Vogel R; White HD; Zahger D; Zeiher AM; Steg PG; Schwartz GG;
    J Am Coll Cardiol; 2020 Jan; 75(2):133-144. PubMed ID: 31948641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial.
    Damask A; Steg PG; Schwartz GG; Szarek M; Hagström E; Badimon L; Chapman MJ; Boileau C; Tsimikas S; Ginsberg HN; Banerjee P; Manvelian G; Pordy R; Hess S; Overton JD; Lotta LA; Yancopoulos GD; Abecasis GR; Baras A; Paulding C;
    Circulation; 2020 Feb; 141(8):624-636. PubMed ID: 31707832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial.
    Ostadal P; Steg PG; Poulouin Y; Bhatt DL; Bittner VA; Chua T; Diaz R; Goodman SG; Huo Y; Jukema JW; Karpov Y; Pordy R; Scemama M; Szarek M; White HD; Schwartz GG;
    Lancet Diabetes Endocrinol; 2022 May; 10(5):330-340. PubMed ID: 35378068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.
    Schwartz GG; Gabriel Steg P; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Jukema JW; Kim YU; Li QH; Manvelian G; Pordy R; Sourdille T; White HD; Szarek M;
    Circulation; 2021 Mar; 143(11):1109-1122. PubMed ID: 33438437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Alirocumab on Mortality After Acute Coronary Syndromes.
    Steg PG; Szarek M; Bhatt DL; Bittner VA; Brégeault MF; Dalby AJ; Diaz R; Edelberg JM; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Lecorps G; Mahaffey KW; Moryusef A; Ostadal P; Parkhomenko A; Pordy R; Roe MT; Tricoci P; Vogel R; White HD; Zeiher AM; Schwartz GG
    Circulation; 2019 Jul; 140(2):103-112. PubMed ID: 31117810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests.
    Szarek M; Reijnders E; Jukema JW; Bhatt DL; Bittner VA; Diaz R; Fazio S; Garon G; Goodman SG; Harrington RA; Ruhaak LR; Schwertfeger M; Tsimikas S; White HD; Steg PG; Cobbaert C; Schwartz GG;
    Circulation; 2024 Jan; 149(3):192-203. PubMed ID: 37632469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery.
    Goodman SG; Aylward PE; Szarek M; Chumburidze V; Bhatt DL; Bittner VA; Diaz R; Edelberg JM; Hanotin C; Harrington RA; Jukema JW; Kedev S; Letierce A; Moryusef A; Pordy R; Ramos López GA; Roe MT; Viigimaa M; White HD; Zeiher AM; Steg PG; Schwartz GG;
    J Am Coll Cardiol; 2019 Sep; 74(9):1177-1186. PubMed ID: 31466614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control.
    Ray KK; Ginsberg HN; Davidson MH; Pordy R; Bessac L; Minini P; Eckel RH; Cannon CP
    Circulation; 2016 Dec; 134(24):1931-1943. PubMed ID: 27777279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis.
    Sinnaeve PR; Schwartz GG; Wojdyla DM; Alings M; Bhatt DL; Bittner VA; Chiang CE; Correa Flores RM; Diaz R; Dorobantu M; Goodman SG; Jukema JW; Kim YU; Pordy R; Roe MT; Sy RG; Szarek M; White HD; Zeiher AM; Steg PG;
    Eur Heart J; 2020 Jun; 41(24):2248-2258. PubMed ID: 31732742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
    Schwartz GG; Szarek M; Bittner VA; Diaz R; Goodman SG; Jukema JW; Landmesser U; López-Jaramillo P; Manvelian G; Pordy R; Scemama M; Sinnaeve PR; White HD; Gabriel Steg P;
    J Am Coll Cardiol; 2021 Aug; 78(5):421-433. PubMed ID: 34325831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
    Schwartz GG; Steg PG; Szarek M; Bittner VA; Diaz R; Goodman SG; Kim YU; Jukema JW; Pordy R; Roe MT; White HD; Bhatt DL;
    Circulation; 2020 May; 141(20):1608-1617. PubMed ID: 32223446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial.
    Bhatt DL; Briggs AH; Reed SD; Annemans L; Szarek M; Bittner VA; Diaz R; Goodman SG; Harrington RA; Higuchi K; Joulain F; Jukema JW; Li QH; Mahaffey KW; Sanchez RJ; Roe MT; Lopes RD; White HD; Zeiher AM; Schwartz GG; Gabriel Steg P;
    J Am Coll Cardiol; 2020 May; 75(18):2297-2308. PubMed ID: 32381160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.
    Szarek M; Bittner VA; Aylward P; Baccara-Dinet M; Bhatt DL; Diaz R; Fras Z; Goodman SG; Halvorsen S; Harrington RA; Jukema JW; Moriarty PM; Pordy R; Ray KK; Sinnaeve P; Tsimikas S; Vogel R; White HD; Zahger D; Zeiher AM; Steg PG; Schwartz GG;
    Eur Heart J; 2020 Nov; 41(44):4245-4255. PubMed ID: 33051646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial.
    Schwartz GG; Szarek M; Bhatt DL; Bittner VA; Bujas-Bobanovic M; Diaz R; Fazio S; Fras Z; Goodman SG; Harrington RA; Jukema JW; Manvelian G; Pordy R; Ray KK; Scemama M; White HD; Steg PG;
    Eur Heart J; 2023 Mar; 44(16):1408-17. PubMed ID: 36879424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study.
    Bittner VA; Schwartz GG; Bhatt DL; Chua T; De Silva HA; Diaz R; Goodman SG; Harrington RA; Jukema JW; McGinniss J; Pordy R; Garon G; Scemama M; White HD; Steg PG; Szarek M;
    J Clin Lipidol; 2024 Apr; ():. PubMed ID: 38960812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome.
    Steg PG; Szarek M; Valgimigli M; Islam S; Zeiher AM; Bhatt DL; Bittner VA; Chiang CE; Diaz R; Goodman SG; Gotcheva N; Harrington RA; Jukema JW; Kim HS; Kim SH; Morais J; Pordy R; Scemama M; White HD; Schwartz GG;
    Can J Cardiol; 2023 Oct; 39(10):1315-1324. PubMed ID: 37116789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
    Ray KK; Vallejo-Vaz AJ; Ginsberg HN; Davidson MH; Louie MJ; Bujas-Bobanovic M; Minini P; Eckel RH; Cannon CP
    Atherosclerosis; 2019 Sep; 288():194-202. PubMed ID: 31253441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
    Roe MT; Li QH; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Harrington RA; Jukema JW; Lopez-Jaramillo P; Lopes RD; Louie MJ; Moriarty PM; Szarek M; Vogel R; White HD; Zeiher AM; Baccara-Dinet MT; Steg PG; Schwartz GG
    Circulation; 2019 Nov; 140(19):1578-1589. PubMed ID: 31475572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.